Studies Currently Enrolling

For participants without memory loss
For participants with and without memory loss
For participants with memory loss

Brain Imaging, APOE & the Preclinical Course of Alzheimer’s Disease Study

ClinicalTrials.gov identifier: n/a

Ages Eligible for Study:

47-68 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.

Studies for participants without memory loss

API Generation 1 Study: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (NCT02565511 (opens in new window))

Learn more: Generation Study   

API Generation 2 Study: A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (NCT03131453 (opens in new window))

Learn more: Generation Study   

GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype (NCT02564692 (opens in new window))

Learn more: GeneMatch   

Studies for participants with and without memory loss

Alzheimer’s Disease Core Center (ADCC) (NCT01421420 (opens in new window))

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (NCT02854033 (opens in new window))

Learn more: ADNI 3 (opens in new window)

Studies for participants with memory loss

Aware – A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease (NCT02880956 (opens in new window))

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer’s Disease – Phase 2a Study (NCT02580305 (opens in new window))

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (NCT03518073 (opens in new window))

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO) (NCT03352557 (opens in new window))

A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) (NCT03367403 (opens in new window))

Top